Sick leave request following anti-COVID-19 vaccine administration is low among healthcare workers: results from a retrospective cross-sectional monocentric study

Eur Rev Med Pharmacol Sci. 2021 Dec;25(23):7218-7222. doi: 10.26355/eurrev_202112_27414.

Abstract

Objective: Anti-COVID-19 vaccines were mainly associated with non-serious adverse events (AEs), whose prevalence was reported to be up to 70% in healthcare workers (HCWs). This may lead to sick leave requests, but this impact has never been quantified. This study aimed to investigate the absence from work among HCWs following anti-COVID-19 vaccination. Its association with age and previous COVID-19 infection was also assessed.

Patients and methods: This is a retrospective observational cross-sectional study on administrative data about sick leave requests after anti-COVID-19 vaccination. All the HCWs employed at the Niguarda Hospital (Milan, Italy) who received the vaccine from December 27, 2020 to February 28, 2021 were included.

Results: In total, 4,088 HCWs received the first dose of the vaccine and 4,043 completed the vaccination cycle. After the first injection, 1.6% of HCWs requested sick leave, while after the second injection, the number of requests significantly increased (+6.1%, p<0.001). A significant increase in sick leave was detected for those who have had SARS-CoV-2 infection after the first injection (+2.3%, p<0.001). After the second dose, a significant increase in sick leave was observed in the 20-30-year-old group compared to >30 years (+3.6%, p=0.017), if HCWs without a history of SARS-CoV-2 infection were considered.

Conclusions: The requests for sick leave among HCWs following the anti-COVID-19 vaccine were limited and higher after the second injection. This may help the management of the human resources when the large-scale administration of the anti-COVID-19 vaccines will involve other categories of workers.

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Age Factors
  • BNT162 Vaccine / administration & dosage*
  • BNT162 Vaccine / adverse effects
  • COVID-19 / prevention & control*
  • Cross-Sectional Studies
  • Female
  • Health Personnel / statistics & numerical data*
  • Humans
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Prevalence
  • Retrospective Studies
  • Sick Leave / statistics & numerical data*
  • Young Adult

Substances

  • BNT162 Vaccine